Literature DB >> 23896201

Relationships between serum leptin level and severity of positive symptoms in schizophrenia.

Yoichiro Takayanagi1, Nicola G Cascella, Debby Santora, Patricia E Gregory, Akira Sawa, William W Eaton.   

Abstract

The adipocytokine leptin is a key mediator of energy homeostasis. Recent papers have suggested that leptin may also have roles in the brain however it is unclear whether leptin is connected to symptoms of mental disorders. In this study, we sought to clarify the relationships between serum leptin level and psychopathology in schizophrenia (SZ) patients. The severity of positive symptoms inversely correlated with the serum leptin levels among SZ patients. There was no correlation between leptin levels and negative symptoms or neurocognition. Our data suggest a role of leptin in SZ positive symptoms.
Copyright © 2013. Published by Elsevier Ireland Ltd.

Entities:  

Keywords:  Cognitive function; Leptin; Metabolic syndrome; Negative symptom; Positive symptoms; Schizophrenia

Mesh：

Substances：

Year:  2013        PMID： 23896201      PMCID： PMC3936335          DOI： 10.1016/j.neures.2013.07.003

Source DB:  PubMed          Journal:  Neurosci Res        ISSN： 0168-0102            Impact factor:   3.304


  20 in total

1.  A longitudinal study on the impact of antipsychotic treatment on serum leptin in schizophrenia.

Authors:  Ganesan Venkatasubramanian; Seetharamaiah Chittiprol; Narendran Neelakantachar; Taranath K Shetty; Bangalore N Gangadhar
Journal:  Clin Neuropharmacol       Date:  2010 Nov-Dec       Impact factor: 1.592

2.  Leptin and HDL-cholesterol in non-diabetic normotensive subjects.

Authors:  G M Marinari; N Scopinaro; G F Adami
Journal:  Obes Surg       Date:  2001-06       Impact factor: 4.129

3.  Baseline neurocognitive deficits in the CATIE schizophrenia trial.

Authors:  Richard S E Keefe; Robert M Bilder; Philip D Harvey; Sonia M Davis; Barton W Palmer; James M Gold; Herbert Y Meltzer; Michael F Green; Del D Miller; Jose M Canive; Lawrence W Adler; Theo C Manschreck; Marvin Swartz; Robert Rosenheck; Diana O Perkins; Trina M Walker; T Scott Stroup; Joseph P McEvoy; Jeffrey A Lieberman
Journal:  Neuropsychopharmacology       Date:  2006-04-19       Impact factor: 7.853

4.  Serum leptin, thyroxine and thyroid-stimulating hormone levels interact to affect cognitive function among US adults: evidence from a large representative survey.

Authors:  May A Beydoun; Hind A Beydoun; Monal R Shroff; Melissa H Kitner-Triolo; Alan B Zonderman
Journal:  Neurobiol Aging       Date:  2011-07-16       Impact factor: 4.673

5.  Is fasting leptin associated with insulin resistance among nondiabetic individuals? The Miami Community Health Study.

Authors:  R P Donahue; R J Prineas; R D Donahue; P Zimmet; J A Bean; M De Courten; G Collier; R B Goldberg; J S Skyler; N Schneiderman
Journal:  Diabetes Care       Date:  1999-07       Impact factor: 19.112

6.  Leptin receptor signaling in midbrain dopamine neurons regulates feeding.

Authors:  Jonathan D Hommel; Richard Trinko; Robert M Sears; Dan Georgescu; Zong-Wu Liu; Xiao-Bing Gao; Jeremy J Thurmon; Michela Marinelli; Ralph J DiLeone
Journal:  Neuron       Date:  2006-09-21       Impact factor: 17.173

7.  Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics.

Authors:  Murad Atmaca; Murat Kuloglu; Ertan Tezcan; Bilal Ustundag
Journal:  J Clin Psychiatry       Date:  2003-05       Impact factor: 4.384

8.  Plasma leptin is associated with insulin resistance independent of age, body mass index, fat mass, lipids, and pubertal development in nondiabetic adolescents.

Authors:  K-C Huang; R C Y Lin; N Kormas; L-T Lee; C-Y Chen; T P Gill; I D Caterson
Journal:  Int J Obes Relat Metab Disord       Date:  2004-04

9.  Neurocognitive assessment in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project schizophrenia trial: development, methodology, and rationale.

Authors:  Richard S E Keefe; Richard C Mohs; Robert M Bilder; Philip D Harvey; Michael F Green; Herbert Y Meltzer; James M Gold; Mary Sano
Journal:  Schizophr Bull       Date:  2003       Impact factor: 9.306

10.  The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development.

Authors:  T Scott Stroup; Joseph P McEvoy; Marvin S Swartz; Matthew J Byerly; Ira D Glick; Jose M Canive; Mark F McGee; George M Simpson; Michael C Stevens; Jeffrey A Lieberman
Journal:  Schizophr Bull       Date:  2003       Impact factor: 9.306
View more
  10 in total

Review 1.  The impact of leptin on perinatal development and psychopathology.

Authors:  Jeanette C Valleau; Elinor L Sullivan
Journal:  J Chem Neuroanat       Date:  2014-05-23       Impact factor: 3.052

2.  Pathway-wide association study identifies five shared pathways associated with schizophrenia in three ancestral distinct populations.

Authors:  C Liu; C A Bousman; C Pantelis; E Skafidas; D Zhang; W Yue; I P Everall
Journal:  Transl Psychiatry       Date:  2017-02-21       Impact factor: 6.222

Review 3.  Peptides from adipose tissue in mental disorders.

Authors:  Andrzej Wędrychowicz; Andrzej Zając; Maciej Pilecki; Barbara Kościelniak; Przemysław J Tomasik
Journal:  World J Psychiatry       Date:  2014-12-22

Review 4.  Effects of Antipsychotics on Bone Mineral Density in Patients with Schizophrenia: Gender Differences.

Authors:  Chien-Yu Chen; Hsien-Yuan Lane; Chieh-Hsin Lin
Journal:  Clin Psychopharmacol Neurosci       Date:  2016-08-31       Impact factor: 2.582

5.  Development of a blood-based molecular biomarker test for identification of schizophrenia before disease onset.

Authors:  M K Chan; M-O Krebs; D Cox; P C Guest; R H Yolken; H Rahmoune; M Rothermundt; J Steiner; F M Leweke; N J M van Beveren; D W Niebuhr; N S Weber; D N Cowan; P Suarez-Pinilla; B Crespo-Facorro; C Mam-Lam-Fook; J Bourgin; R J Wenstrup; R R Kaldate; J D Cooper; S Bahn
Journal:  Transl Psychiatry       Date:  2015-07-14       Impact factor: 6.222

Review 6.  The Complex Relationship between Antipsychotic-Induced Weight Gain and Therapeutic Benefits: A Systematic Review and Implications for Treatment.

Authors:  Alex T Raben; Victoria S Marshe; Araba Chintoh; Ilona Gorbovskaya; Daniel J Müller; Margaret K Hahn
Journal:  Front Neurosci       Date:  2018-01-22       Impact factor: 4.677

Review 7.  Metabolic and Microbiota Measures as Peripheral Biomarkers in Major Depressive Disorder.

Authors:  Rachael Horne; Jane A Foster
Journal:  Front Psychiatry       Date:  2018-10-22       Impact factor: 4.157

Review 8.  Leptin and psychiatric illnesses: does leptin play a role in antipsychotic-induced weight gain?

Authors:  Francky Teddy Endomba; Aurel T Tankeu; Jan René Nkeck; Joel Noutakdie Tochie
Journal:  Lipids Health Dis       Date:  2020-02-07       Impact factor: 3.876

9.  Association of higher plasma leptin levels with HOMA-IR index, high sensitivity C-reactive protein and glycolipid metabolism in patients with chronic schizophrenia: A multi-center cross-sectional study.

Authors:  Zhiwei Liu; Yulong Zhang; Juan Wang; Lei Xia; Yating Yang; Liang Sun; Dapeng Zhang; Wenzheng Li; Xianhu Yao; Rongchun Yang; Yun Liu; Huanzhong Liu
Journal:  Front Psychiatry       Date:  2022-08-25       Impact factor: 5.435

10.  Expression of NF-κB associated lncRNAs in schizophrenia.

Authors:  Amin Safa; Elham Badrlou; Shahram Arsang-Jang; Arezou Sayad; Mohammad Taheri; Soudeh Ghafouri-Fard
Journal:  Sci Rep       Date:  2020-10-22       Impact factor: 4.379
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.